Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.53 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.53 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.36 |
| ▸ | MAPT | P10636 | 5/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL447822 | 0.82 | HPGD (0.49) | EHMT2EHMT1APOBEC3GHPGDSMN1; SMN2 | |
| SCHEMBL3055553 | 0.80 | EHMT2 (0.50) | EHMT2EHMT1APOBEC3GHPGDSMN1; SMN2 | |
| SCHEMBL860540 | 0.80 | EHMT2 (0.64) | EHMT2EHMT1APOBEC3GHPGDSMN1; SMN2 | |
| SCHEMBL30195057 | 0.80 | EHMT2 (0.64) | EHMT2EHMT1APOBEC3GHPGDSMN1; SMN2 | |
| SCHEMBL24599713 | 0.77 | EHMT2 (0.59) | EHMT2EHMT1APOBEC3GHPGDSMN1; SMN2 | |
| SCHEMBL15301017 | 0.77 | EHMT2 (0.59) | EHMT2EHMT1APOBEC3GHPGDSMN1; SMN2 | |
| SCHEMBL803314 | 0.77 | EHMT2 (0.59) | EHMT2EHMT1APOBEC3GHPGDSMN1; SMN2 | |
| SCHEMBL1271372 | 0.77 | EHMT2 (0.59) | EHMT2EHMT1APOBEC3GHPGDSMN1; SMN2 | |
| SCHEMBL16132722 | 0.77 | EHMT2 (0.59) | EHMT2EHMT1APOBEC3GHPGDSMN1; SMN2 | |
| SCHEMBL16486465 | 0.77 | EHMT2 (0.59) | EHMT2EHMT1APOBEC3GHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6890533-B2 | Betulinol derivatives | CORNELL RESEARCH FOUNDATION, INC. (US) | 2005-05-10 | — | — | US | claimed |
| EP-1473301-A2 | Betulinol derivatives | CORNELL RESEARCH FOUNDATION, INC. (US) | 2004-11-03 | — | — | EP | claimed |
| US-20040001837-A1 | Anticancer complex | BOMSHTEYN, ARKADIY | 2004-01-01 | — | — | US | claimed |
| US-20030036540-A1 | Betulinol derivatives | BOMSHTEYN, ARKADIY | 2003-02-20 | — | — | US | claimed |
| EP-0988311-A4 | BETULINOL DERIVATIVES | CORNELL RES FOUNDATION INC (US) | 2003-02-05 | — | — | EP | claimed |
| EP-0988311-A1 | BETULINOL DERIVATIVES | CORNELL RESEARCH FOUNDATION, INC. (US) | 2000-03-29 | — | — | EP | claimed |
| WO-1998055497-A1 | BETULINOL DERIVATIVES | CORNELL RESEARCH FOUNDATION, INC. (US) | 1998-12-10 | — | — | WO | claimed |
| CN-108430514-B | Compositions and methods for treating peroxisome disorders and leukodystrophies | 约翰霍普金斯大学 | 2023-11-03 | — | — | CN | disclosed |
| EP-3368088-B1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PEROXISOMAL DISORDERS AND LEUKODYSTROPHIES | UNIV JOHNS HOPKINS (US) | 2023-06-07 | — | — | EP | disclosed |
| WO-2023080159-A1 | LIGAND-BOUND NUCLEIC ACID COMPLEX | レナセラピューティクス株式会社 | 2023-05-11 | — | — | WO | disclosed |
| CN-114392360-A | Dendrimer compositions and use in the treatment of neurological and CNS disorders | 约翰霍普金斯大学 | 2022-04-26 | — | — | CN | disclosed |
| US-20210154323-A1 | FUNCTIONALIZED NANOPARTICLES FOR THE INTRACELLULAR DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES AND METHODS FOR THEIR MANUFACTURE AND USE | STEMGENICS, INC. (US) | 2021-05-27 | — | — | US | disclosed |
| CN-108289872-B | Dendrimer compositions and their use in the treatment of necrotizing enterocolitis and other gastrointestinal disorders | 约翰霍普金斯大学 | 2021-04-02 | — | — | CN | disclosed |
| US-4661347-A | Cytotoxic compositions | SCRIPPS CLINIC (US) | 1987-04-28 | — | — | US | disclosed |
| EP-0152736-A2 | Enzyme-protein conjugate, process for its preparation and pharmaceutical composition | BEECHAM GROUP PLC (GB) | 1985-08-28 | — | — | EP | disclosed |
| EP-0152255-A2 | New renin-inhibitory peptides and their use | SANKYO COMPANY LIMITED (JP) | 1985-08-21 | — | — | EP | disclosed |
| US-4529712-A | Amino reactive end of a heterobifunctional crosslinking reagent connects to thiol reactive compound | RESEARCH CORPORATION (US) | 1985-07-16 | — | — | US | disclosed |
| US-4429008-A | AGGLUTINATION ASSAYS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1984-01-31 | — | — | US | disclosed |
| EP-0097691-A1 | THIOL REACTIVE LIPOSOMES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1984-01-11 | — | — | EP | disclosed |
| WO-1983002069-A1 | THIOL REACTIVE LIPOSOMES | UNIV CALIFORNIA (US) | 1983-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210154323-A1 | FUNCTIONALIZED NANOPARTICLES FOR THE INTRACELLULAR DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES AND METHODS FOR THEIR MANUFACTURE AND USE | CD47, CD44, LNPK | EHMT2 2189/4885EHMT1 2271/4885APOBEC3G 1267/4885 |
| US-20040001837-A1 | Anticancer complex | BET1, TMPO, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | EHMT2 671/4885EHMT1 720/4885APOBEC3G 1327/4885 |
| US-20030036540-A1 | Betulinol derivatives | BET1, TMPO, HRH3 | EHMT2 403/4885EHMT1 436/4885APOBEC3G 1468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.